-
Mashup Score: 1
PRNEWS looked at announcements made this week by TikTok, the publishing industry and Eli Lilly, hoping to improve the lives of those impacted.
Source: PRNEWSCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
This decision was based from the analysis of the company’s phase 2 BLAZE-4 trial.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
Results from two phase 3 trials evaluating tirzepatide in adults with type 2 diabetes showed statistically significant HbA1c and body weight reductions.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
Results from two phase 3 trials evaluating tirzepatide in adults with type 2 diabetes showed statistically significant HbA1c and body weight reductions.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 3FDA approves emergency use of antibody to treat COVID-19 - 4 year(s) ago
Dr. Marc Siegel weighs in on ‘America’s Newsroom.’
Source: Fox NewsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 606
U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t…
Source: MarketWatchCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0FDA Panel Votes on Ramucirumab for First-Line Treatment of Metastatic EGFR-Positive NSCLC - MPR - 4 year(s) ago
The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab (Cyramza; Lilly) plus erlotinib demonstrated a favorable benefit/risk profile for patients with untreated metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). The vote was based on data from the phase 3 RELAY study (N=449), which evaluated…
Source: MPRCategories: General Medicine Journals and SocietiesTweet
GREAT READ: @PRNews Roundup: #TikTok Screen Time, #Dilbert Done, #EliLilly's #Reputation by @Buffalogal. Hear my thoughts on the #Lilly #diabetes pricing included in Nicole's reputation roundup. #pharmapricing #PBMs #Medicare #Access https://t.co/oi2Fd9B9Kc